CellaVision ABCVLLY +12.06%69 Current Ratio is 3.80 as of Mar. 2026, which is 18% above its 10-year median of 3.21. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, CellaVision AB ranks better than 67.68% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CellaVision AB's current ratio for the quarter that ended in Mar. 2026 was 3.80.
CellaVision AB has a current ratio of 3.80. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for CellaVision AB's Current Ratio or its related term are showing as below:
CVLLY'
s Current Ratio Range Over the Past 10 Years
Min: 2.11 Med: 3.21 Max: 5.04
Current: 3.8
During the past 13 years, CellaVision AB's highest Current Ratio was 5.04. The lowest was 2.11. And the median was 3.21.
CVLLY's Current Ratio is ranked better than 67.68% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs CVLLY: 3.80
CellaVision AB (OTCPK:CVLLY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
CellaVision AB Current Ratio Related Terms
CellaVision AB Current Ratio Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a Current Ratio of 3.80 as of Mar. 2026. This is 18% above median its historical median of 3.21. Over the past decade, CellaVision AB's Current Ratio has ranged from 2.11 to 5.04. According to the industry distribution chart, CellaVision AB ranks #276 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 32.3%.
Is CellaVision AB's Current Ratio too high?
CellaVision AB's current Current Ratio of 3.80 is 18% above median its 10-year median of 3.21. Over the past 10 years, this metric has ranged from a low of 2.11 to a high of 5.04. The Medical Devices & Instruments industry median Current Ratio is 2.49. CellaVision AB's value of 3.80 is 52.6% above this industry median. Based on the distribution chart, CellaVision AB ranks #276 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #276 out of 854 companies for Current Ratio. This puts CellaVision AB in the upper half of its industry. The industry median Current Ratio is 2.49. CellaVision AB's value of 3.80 is 52.6% above this benchmark. Historically, CellaVision AB's own Current Ratio has ranged from 2.11 to 5.04 over the past decade. While the company's 10-year median is 3.21 vs. the industry median of 2.49, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Current Ratio of 3.80 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Current Ratio is 3.80, which is 18% above median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Current Ratio is 3.80, which is 18% above median its 10-year median of 3.21 and 52.6% above the Medical Devices & Instruments industry median of 2.49. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Current Ratio is 3.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
Current Ratio: 3.80 (18% above median its 10-year median of 3.21)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 52.6% above the Medical Devices & Instruments median (#276 of 854)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
